Abstract
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), sometimes referred to as the novel coronavirus (2019-nCoV), is currently a worldwide threat to public health. According to the Johns Hopkins University monitor (available at, coronavirus.jhu.edu/map), there have been more than 10 million reported cases of coronavirus 2019 disease (COVID-19) and 500,000 deaths as of June 29, 2020, deeming urgent the identification of a drug candidate and treatment regimen.
Objective: This work aims to compile the current knowledge available on this drug, including its background, approved uses, some synthetic methods, the primary pharmacological aspects, the results against COVID-19 reported so far, and ongoing clinical trials against COVID-19.
Methods: We reviewed relevant press releases, scientific articles, and official documents to compile information about Favipiravir.
Results: We highlight, in a clear and concise form, not only the published and ongoing clinical trials on the use of Favipiravir against COVID-19 but also compile some relevant synthetic and pharmacological information available about this drug.
Conclusion: The Antiviral Favipiravir has shown interesting preliminary results, but it seems too early to recommend a treatment protocol for COVID-19 based on this drug. Robust clinical trials that will provide less biased data on its efficacy and safety are being pushed forward by FUJIFILM Corporation and by research groups around the globe.
Keywords: Coronavirus, COVID-19, favipiravir, synthesis, mechanism of action, pharmacology
Coronaviruses
Title:Favipiravir in the Spotlight: In Search of Treatment Against COVID-19
Volume: 2 Issue: 1
Author(s): Victor Facchinetti and Marcus Vinícius Nora de Souza*
Affiliation:
- Fundacao Oswaldo Cruz, Instituto de Tecnologia em Farmacos, Rua Sizenando Nabuco 100, Rio de Janeiro, RJ,Brazil
Keywords: Coronavirus, COVID-19, favipiravir, synthesis, mechanism of action, pharmacology
Abstract:
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), sometimes referred to as the novel coronavirus (2019-nCoV), is currently a worldwide threat to public health. According to the Johns Hopkins University monitor (available at, coronavirus.jhu.edu/map), there have been more than 10 million reported cases of coronavirus 2019 disease (COVID-19) and 500,000 deaths as of June 29, 2020, deeming urgent the identification of a drug candidate and treatment regimen.
Objective: This work aims to compile the current knowledge available on this drug, including its background, approved uses, some synthetic methods, the primary pharmacological aspects, the results against COVID-19 reported so far, and ongoing clinical trials against COVID-19.
Methods: We reviewed relevant press releases, scientific articles, and official documents to compile information about Favipiravir.
Results: We highlight, in a clear and concise form, not only the published and ongoing clinical trials on the use of Favipiravir against COVID-19 but also compile some relevant synthetic and pharmacological information available about this drug.
Conclusion: The Antiviral Favipiravir has shown interesting preliminary results, but it seems too early to recommend a treatment protocol for COVID-19 based on this drug. Robust clinical trials that will provide less biased data on its efficacy and safety are being pushed forward by FUJIFILM Corporation and by research groups around the globe.
Export Options
About this article
Cite this article as:
Facchinetti Victor and de Souza Marcus Vinícius Nora*, Favipiravir in the Spotlight: In Search of Treatment Against COVID-19, Coronaviruses 2021; 2 (1) : e160223184322 . https://dx.doi.org/10.2174/2666796701999200729155347
DOI https://dx.doi.org/10.2174/2666796701999200729155347 |
Print ISSN 2666-7967 |
Publisher Name Bentham Science Publisher |
Online ISSN 2666-7975 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Differences Among Sexes in Blood Pressure: A Combinatorial Consequence
of the Differences between RAAS Components, Sex Hormones,
and Time Course
Current Hypertension Reviews Effects of Nanosuspension Formulations on Transport, Pharmacokinetics, In Vivo Targeting and Efficacy for Poorly Water-soluble Drugs
Current Pharmaceutical Design Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Iron Oxide Nano Particles and its Applications to Cure HER2-Positive Mediated Breast Cancer
Current Nanomedicine Dihydro-alkoxyl-benzyl-oxopyrimidine Derivatives (DABOs) As Non-Nucleoside Reverse Transcriptase Inhibitors: An Update Review (2001-2011)
Current Medicinal Chemistry <i>In Silico</i> Insight into the Inhibitory Effects of Active Antidiabetic Compounds from Medicinal Plants Against SARS-CoV-2 Replication and Posttranslational Modification
Coronaviruses Epidemiological Study of COVID-19 in Iran and the World: A Review Study
Infectious Disorders - Drug Targets Peptide Targeted Copper-64 Radiopharmaceuticals
Current Topics in Medicinal Chemistry Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design Molecular Docking Studies for Protein-Targeted Drug Development in SARS-CoV-2
Letters in Drug Design & Discovery ABC Transporters and the Blood-Brain Barrier
Current Pharmaceutical Design Therapeutic Utility and Medicinal Chemistry of Cathepsin C Inhibitors
Current Topics in Medicinal Chemistry Natural Sesquiterpene Lactones in the Prevention and Treatment of Inflammatory Disorders and cancer: A Systematic Study of this Emerging Therapeutic Approach based on Chemical and Pharmacological Aspect
Letters in Drug Design & Discovery Inhibitors of Cyclin Dependent Kinases: Useful Targets for Cancer Treatment
Current Cancer Drug Targets Versatile Synthesis of Organic Compounds Derived from Ascorbic Acid
Current Organocatalysis State of the Art Management of Transfusion-Related Acute Lung Injury (TRALI)
Current Pharmaceutical Design An Overview of Partial Synthesis and Transformations of Secosteroids
Current Organic Chemistry Small Molecule Inhibitors of Human Adipocyte Fatty Acid Binding Protein (FABP4)
Medicinal Chemistry Motor Unit and Neuromuscular Junction Remodeling with Aging
Current Aging Science Review on <i>In Silico</i> Methods, High-throughput Screening Techniques, and Cell Culture Based <i>In Vitro</i> Assays for SARS-CoV-2
Current Medicinal Chemistry